Mark Schoenberg
Chief Tech/Sci/R&D Officer presso UROGEN PHARMA LTD.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Mark P.
Schoenberg is currently the Chief Medical Officer at UroGen Pharma Ltd.
He is also a Member of The American Association of Cancer Research, the Society of Urologic Nurses & Associates, and the Society of Urologic Oncology, Inc. Previously, he worked as a Professor at The Johns Hopkins University from 2005 to 2014 and as the Chief Medical Officer at Sonablate Corp.
Dr. Schoenberg completed his undergraduate degree at Yale University and his doctorate at the University of Texas Health Center.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
UROGEN PHARMA LTD.
0.41% | 18/03/2024 | 139 437 ( 0.41% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Mark Schoenberg
| Società | Posizione | Inizio |
|---|---|---|
| UROGEN PHARMA LTD. | Chief Tech/Sci/R&D Officer | 09/02/2016 |
| The American Association of Cancer Research | Corporate Officer/Principal | - |
| Society of Urologic Oncology, Inc. | Corporate Officer/Principal | - |
Society of Urologic Nurses & Associates
 Society of Urologic Nurses & Associates Miscellaneous Commercial ServicesCommercial Services Society of Urologic Nurses & Associates operates as a nonprofit organization. The firm supports urologic health care professionals. It specializes in advancing urologic nursing practice and patient care. The company was founded in 1972 and is headquartered in Pitman, NJ. | Corporate Officer/Principal | - |
Precedenti posizioni note di Mark Schoenberg
| Società | Posizione | Fine |
|---|---|---|
| The Johns Hopkins University | Corporate Officer/Principal | 01/01/2014 |
Sonablate Corp.
 Sonablate Corp. Medical SpecialtiesHealth Technology Sonablate Corp. develops and manufactures high intensity focused ultrasound surgical ablation systems. Its products include Sonablate 450, a HIFU solution that determines the safety and efficacy of a minimally invasive prostate cancer treatment; Sonablate 500, a HIFU surgical ablation system for the treatment of localized prostate cancer that delivers ablative therapy with the possibility of reducing side effects; and Sonatherm, a laparoscopic HIFU surgical ablation system that uses a laparoscopic probe to deliver robotic ablative therapy to soft tissue with a customizable ablation zone. The company was founded by Stephen R. Puckett Sr. and George M. Suarez in 2004 and is headquartered in Charlotte, NC. | Chief Tech/Sci/R&D Officer | - |
Formazione di Mark Schoenberg
| Yale University | Undergraduate Degree |
| University of Texas Health Center | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| UROGEN PHARMA LTD. | Health Technology |
| Aziende private | 4 |
|---|---|
Society of Urologic Nurses & Associates
Society of Urologic Nurses & Associates Miscellaneous Commercial ServicesCommercial Services Society of Urologic Nurses & Associates operates as a nonprofit organization. The firm supports urologic health care professionals. It specializes in advancing urologic nursing practice and patient care. The company was founded in 1972 and is headquartered in Pitman, NJ. | Commercial Services |
Sonablate Corp.
Sonablate Corp. Medical SpecialtiesHealth Technology Sonablate Corp. develops and manufactures high intensity focused ultrasound surgical ablation systems. Its products include Sonablate 450, a HIFU solution that determines the safety and efficacy of a minimally invasive prostate cancer treatment; Sonablate 500, a HIFU surgical ablation system for the treatment of localized prostate cancer that delivers ablative therapy with the possibility of reducing side effects; and Sonatherm, a laparoscopic HIFU surgical ablation system that uses a laparoscopic probe to deliver robotic ablative therapy to soft tissue with a customizable ablation zone. The company was founded by Stephen R. Puckett Sr. and George M. Suarez in 2004 and is headquartered in Charlotte, NC. | Health Technology |
| The American Association of Cancer Research | |
| Society of Urologic Oncology, Inc. |
- Borsa valori
- Insiders
- Mark Schoenberg
